Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Jan-20 1:36 PM View:  | Schuetz Thomas J. Director | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 89,695 | $60.00 | $5,381,700.00 | (100%) 89.69K to 0 | |
| 15-Jan-20 1:38 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 183,384 | $60.00 | $11,003,000.00 | (100%) 183.38K to 0 | |
| 15-Jan-20 1:32 PM View: | Meltz Mark A SVP, General Counsel | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 32,705 | $60.00 | $1,962,300.00 | (100%) 32.7K to 0 | |
| 15-Jan-20 1:26 PM View: | Conner Edward R. SVP, Chief Medical Officer | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 24,584 | $60.00 | $1,475,040.00 | (100%) 24.58K to 0 | |
| 15-Jan-20 1:31 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 49,576 | $60.00 | $2,974,560.00 | (100%) 49.58K to 0 | |
| 15-Jan-20 1:27 PM View: | Goldberg Mark Alan Director | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 1,500 | $60.00 | $90,000.00 | (100%) 1.5K to 0 | |
| 15-Jan-20 1:34 PM View: | Mosbrooker Eric SVP, Chief Commercial Officer | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 26,919 | $60.00 | $1,615,140.00 | (100%) 26.92K to 0 | |
| 15-Jan-20 1:35 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 171,814 | $60.00 | $10,308,800.00 | (100%) 171.81K to 0 | |
| 15-Jan-20 1:29 PM View: | Holles Natalie C. President and COO | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 104,439 | $60.00 | $6,266,340.00 | (100%) 104.44K to 0 | |
| 15-Jan-20 1:31 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 265,799 | $60.00 | $15,947,900.00 | (84%) 315.38K to 49.58K | |
| 15-Jan-20 1:35 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 15-Jan-20 | Disposition (change in control) | 261,458 | $60.00 | $15,687,500.00 | (60%) 433.27K to 171.81K | |
| 10-Jan-20 6:19 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 08-Jan-20 | Option Exercise | 150,888 | $3.28 | $494,897.00 | 464% 32.5K to 183.38K | |
| 10-Jan-20 6:18 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 08-Jan-20 | Option Exercise | 162,538 | $3.10 | $503,567.00 | 60% 270.73K to 433.27K | |
| 10-Jan-20 6:18 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 26-Dec-19 | Gift | 12,500 | -- | -- | (4%) 283.23K to 270.73K | |
| 27-Dec-19 4:10 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 23-Dec-19 | Private Sale (Planned) | 10,000 | $59.60 | $595,993.00 | (3%) 326.38K to 316.38K | |
| 27-Dec-19 4:10 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 23-Dec-19 | Private Sale (Planned) | 1,000 | $59.60 | $59,596.30 | (< 1%) 316.38K to 315.38K | |
| 16-Dec-19 6:03 PM View: | Holles Natalie C. President and COO | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Payment of Exercise | 97,609 | $59.37 | $5,795,050.00 | (48%) 202.05K to 104.44K | |
| 16-Dec-19 6:03 PM View: | Holles Natalie C. President and COO | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Option Exercise | 147,344 | $12.68 | $1,868,990.00 | 269% 54.7K to 202.05K | |
| 16-Dec-19 6:05 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Payment of Exercise | 30,139 | $59.37 | $1,789,350.00 | (48%) 62.63K to 32.5K | |
| 16-Dec-19 6:05 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Option Exercise | 41,321 | $2.76 | $114,248.00 | 194% 21.31K to 62.63K | |
| 16-Dec-19 6:04 PM View: | Meltz Mark A SVP, General Counsel | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Payment of Exercise | 4,628 | $59.37 | $274,764.00 | (12%) 37.33K to 32.7K | |
| 16-Dec-19 6:02 PM View: | Conner Edward R. SVP, Chief Medical Officer | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Payment of Exercise | 5,416 | $59.37 | $321,548.00 | (18%) 30.0K to 24.58K | |
| 16-Dec-19 6:04 PM View: | Mosbrooker Eric SVP, Chief Commercial Officer | Audentes Therapeutics, Inc. (BOLD) | 12-Dec-19 | Payment of Exercise | 4,881 | $59.37 | $289,785.00 | (15%) 31.8K to 26.92K | |
| 09-Dec-19 5:15 PM View: | Holles Natalie C. President and COO | Audentes Therapeutics, Inc. (BOLD) | 05-Dec-19 | Payment of Exercise | 505 | $59.21 | $29,901.00 | (< 1%) 55.21K to 54.7K | |
| 09-Dec-19 5:17 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 05-Dec-19 | Payment of Exercise | 505 | $59.21 | $29,901.00 | (2%) 21.82K to 21.31K | |
| 09-Dec-19 5:16 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 05-Dec-19 | Payment of Exercise | 1,974 | $59.21 | $116,881.00 | (< 1%) 285.21K to 283.23K | |
| 12-Nov-19 5:32 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 08-Nov-19 | Option Exercise | 14,426 | $9.50 | $137,047.00 | 5% 285.21K to 299.63K | |
| 12-Nov-19 5:32 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 08-Nov-19 | Planned Option Sale | 14,426 | $30.00 | $432,780.00 | (5%) 299.63K to 285.21K | |
| 25-Sep-19 6:11 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 23-Sep-19 | Sale (Planned) | 10,000 | $32.16 | $321,616.00 | (3%) 337.38K to 327.38K | |
| 25-Sep-19 6:11 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 23-Sep-19 | Sale (Planned) | 1,000 | $32.18 | $32,182.00 | (< 1%) 327.38K to 326.38K | |
| 09-Sep-19 4:04 PM View: | Holles Natalie C. President and COO | Audentes Therapeutics, Inc. (BOLD) | 05-Sep-19 | Payment of Exercise | 505 | $31.02 | $15,665.10 | (< 1%) 55.71K to 55.21K | |
| 09-Sep-19 4:06 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 05-Sep-19 | Payment of Exercise | 505 | $31.02 | $15,665.10 | (2%) 22.32K to 21.82K | |
| 09-Sep-19 4:05 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 05-Sep-19 | Payment of Exercise | 1,974 | $31.02 | $61,233.50 | (< 1%) 287.18K to 285.21K | |
| 14-Aug-19 10:00 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 12-Aug-19 | Option Exercise | 20,000 | $9.50 | $190,000.00 | 7% 287.18K to 307.18K | |
| 14-Aug-19 10:00 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 12-Aug-19 | Market Option Sale (Planned) | 20,000 | $34.04 | $680,835.00 | (7%) 307.18K to 287.18K | |
| 17-Jul-19 4:26 PM View: | Conner Edward R. SVP, Chief Medical Officer | Audentes Therapeutics, Inc. (BOLD) | 15-Jul-19 | Grant | 30,000 | -- | -- | 100% 0 to 30.0K | |
| 26-Jun-19 4:07 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 24-Jun-19 | Market Sale (Planned) | 1,000 | $38.20 | $38,200.80 | (< 1%) 338.38K to 337.38K | (< 1%) |
| 26-Jun-19 4:07 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 24-Jun-19 | Market Sale (Planned) | 20,000 | $37.77 | $755,413.00 | (6%) 358.38K to 338.38K | (2%) |
| 07-Jun-19 4:40 PM View: | Soloway Thomas P Executive Vice President, CFO | Audentes Therapeutics, Inc. (BOLD) | 05-Jun-19 | Payment of Exercise | 1,009 | $37.31 | $37,645.80 | (4%) 23.33K to 22.32K | < 1% |
| 07-Jun-19 4:41 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 05-Jun-19 | Payment of Exercise | 3,332 | $37.31 | $124,317.00 | (1%) 290.51K to 287.18K | < 1% |
| 07-Jun-19 4:42 PM View: | Prasad Suyash Senior VP & Chief Med Officer | Audentes Therapeutics, Inc. (BOLD) | 05-Jun-19 | Payment of Exercise | 757 | $37.31 | $28,243.70 | (4%) 18.24K to 17.48K | < 1% |
| 07-Jun-19 4:41 PM View: | Holles Natalie C. President and COO | Audentes Therapeutics, Inc. (BOLD) | 05-Jun-19 | Payment of Exercise | 1,009 | $37.31 | $37,645.80 | (2%) 56.72K to 55.71K | < 1% |
| 15-May-19 4:42 PM View: | Prasad Suyash Senior VP & Chief Med Officer | Audentes Therapeutics, Inc. (BOLD) | 13-May-19 | Option Exercise | 10,000 | $0.79 | $7,900.00 | 55% 18.24K to 28.24K | |
| 15-May-19 4:42 PM View: | Prasad Suyash Senior VP & Chief Med Officer | Audentes Therapeutics, Inc. (BOLD) | 13-May-19 | Market Option Sale (Planned) | 10,000 | $36.98 | $369,798.00 | (35%) 28.24K to 18.24K | |
| 01-Apr-19 5:54 PM View: | Meltz Mark A SVP, General Counsel | Audentes Therapeutics, Inc. (BOLD) | 28-Mar-19 | Grant | 37,333 | -- | -- | 100% 0 to 37.33K | |
| 27-Mar-19 5:03 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 25-Mar-19 | Market Sale (Planned) | 20,000 | $36.00 | $720,015.00 | (5%) 379.93K to 359.93K | (2%) |
| 27-Mar-19 5:03 PM View: | Lange Louis G Director | Audentes Therapeutics, Inc. (BOLD) | 25-Mar-19 | Market Sale (Planned) | 1,558 | $35.98 | $56,058.40 | (< 1%) 359.93K to 358.38K | (2%) |
| 27-Feb-19 4:32 PM View: | Prasad Suyash Senior VP & Chief Med Officer | Audentes Therapeutics, Inc. (BOLD) | 25-Feb-19 | Option Exercise | 10,000 | $0.79 | $7,900.00 | 55% 18.24K to 28.24K | |
| 27-Feb-19 4:32 PM View: | Prasad Suyash Senior VP & Chief Med Officer | Audentes Therapeutics, Inc. (BOLD) | 25-Feb-19 | Market Option Sale (Planned) | 10,000 | $30.06 | $300,553.00 | (35%) 28.24K to 18.24K | |
| 27-Feb-19 4:31 PM View: | Patterson Matthew R Chief Executive Officer Director | Audentes Therapeutics, Inc. (BOLD) | 25-Feb-19 | Option Exercise | 21,000 | $1.05 | $22,020.00 | 7% 290.51K to 311.51K |
